Cochrane Abstracts
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Single or Combined Immune Checkpoint Inhibitors Compared to First‐line Platinum‐based Chemotherapy With or Without Bevacizumab for People With Advanced Non‐small Cell Lung Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433368/all/Single_or_combined_immune_checkpoint_inhibitors_compared_to_first‐line_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_people_with_advanced_non‐small_cell_lung_cancer.
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433368/all/Single_or_combined_immune_checkpoint_inhibitors_compared_to_first‐line_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_people_with_advanced_non‐small_cell_lung_cancer. Accessed December 13, 2024.
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433368/all/Single_or_combined_immune_checkpoint_inhibitors_compared_to_first‐line_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_people_with_advanced_non‐small_cell_lung_cancer
Single or Combined Immune Checkpoint Inhibitors Compared to First‐line Platinum‐based Chemotherapy With or Without Bevacizumab for People With Advanced Non‐small Cell Lung Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433368/all/Single_or_combined_immune_checkpoint_inhibitors_compared_to_first‐line_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_people_with_advanced_non‐small_cell_lung_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
ID - 433368
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433368/all/Single_or_combined_immune_checkpoint_inhibitors_compared_to_first‐line_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_people_with_advanced_non‐small_cell_lung_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
